AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
UBS Reiterates Hold Rating for Ionis Pharmaceuticals with $46 Price Target
ByAinvest
Tuesday, Aug 12, 2025 10:33 pm ET1min read
UBS has maintained a Hold rating for Ionis Pharmaceuticals with a price target of $46.00. The company's shares opened at $40.87. Additionally, Ionis Pharmaceuticals received a Hold from TR | OpenAI – 4o's Dex Genotek and a Buy rating from Leerink Partners. The company has a one-year high of $50.43 and a one-year low of $23.95, with an average volume of 1.8M.
UBS has maintained a Hold rating for Ionis Pharmaceuticals (IONS), with a price target of $46.00, as reported by Esther Rajavelu. The company's shares opened at $40.87 on July 2, 2025. This rating reflects recent performance and strategic developments at Ionis, which has been focused on advancing its portfolio of RNA-targeting therapeutics.Key metrics from the second quarter of 2025 highlight the company's operational efficiency and financial health. Revenue (GAAP) for Q2 2025 was $2.92 million, falling short of the $9.43 million analyst estimate. Research and development expenses (GAAP) jumped 77.3% year over year, primarily due to increased clinical program expenses for zelenectide pevedotin development. Despite the increase in R&D expenses, the cash balance remains substantial at $721.5 million as of Q2 2025 (GAAP), though net loss (GAAP) increased to $(1.14) per share from $(0.77) per share in Q2 2024 [1].
Looking ahead, investors may wish to monitor updates on the Duravelo-2 trial for zelenectide pevedotin, with dose selection and possible U.S. FDA pathway clarification expected in Q4 2025. Progress with its BRC radioconjugates and milestones from its ongoing partnerships are also anticipated as events that could generate value or update investors in the next reporting periods [1].
Ionis Pharmaceuticals received a Hold rating from TR | OpenAI – 4o's Dex Genotek and a Buy rating from Leerink Partners. The company has a one-year high of $50.43 and a one-year low of $23.95, with an average volume of 1.8 million shares.
References:
[1] https://www.ainvest.com/news/ionis-pharmaceuticals-neutral-rating-ubs-46-price-target-2508/
[2] https://www.tradingview.com/news/tradingview:7a43027da8bc8:0-ionis-pharmaceuticals-officer-sells-shares/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet